Leukopaks are highly-enriched leukapheresis-derived products obtained from an IRB-approved collection facility. Leukopaks contain higher concentrations of mononuclear cells, B cells, T cells, stem/progenitor cells, dendritic cells, and other cell types as compared to standard venipuncture collection methods or buffy coat products. Healthy, consented donors undergo a medical screening evaluation and are administered 5 doses of 10ug/kg TBW of Neupogen (filgrastim) on each of 5 days per IRB approved protocols prior to Leukapheresis. Leukapheresis is performed on the 5th and 6th day using the Spectra Optia® Apheresis System following IRB-approved protocols. MNC rich cells are continuously collected from 2-2.5 donor blood volumes into a sterile bag using ACD-A as an anticoagulant. Approximately 120mL of autologous plasma is automatically collected directly into the cell pool following leukapheresis. After a sample is withdrawn for quality testing, a nominal volume of 290mL is transferred into a sterile transfer bag prior to shipping. The total nucleated cell count is determined using AO/PI from the collection and provided as information. Cell counts and CD34 quantities will vary based on the donor's response to mobilization. The total nucleated cell count is determined using AO/PI from the combined pool and provided as information. Fresh mobilized leukapheresis products typically contain up to 1% CD34+ cells, 40% granulocytes, and 5% hematocrit. Exact percentages will vary from donor to donor.
English
Deutsch
